Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs ThredUp Inc (TDUP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs ThredUp Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.59 (market cap $6.04B), while ThredUp Inc trades at $2.47 (market cap $308.63M). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 19.6× ThredUp Inc's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, ThredUp Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and ThredUp Inc for 29 Days on average.
| IOVA | TDUP | |
|---|---|---|
Market Cap | $6.04B | $308.63M |
Volume | 14,805,993 | 3,024,364 |
Sector | Health | Consumer Cyclical |
52-Week High | $14.82 | $9.41 |
52-Week Low | $1.81 | $2.12 |
Typical Hold Time | 0 Days | 29 Days |
Enterprise Value | $5.97B | $306.81M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ThredUp (TDUP) trades at $2.455, up 10.59% in the past 24 hours, with a bearish technical signal but strong analyst support. The company reported record Q2 2026 revenue of $90.8 million, up 17% year-over-year, but missed earnings expectations with a net loss. Fundamentals show a high gross margin of 79.52% but negative net income margin and ROE, while cash flow from operations improved to $10.65 million in 2025.
The outlook is mixed: analyst consensus is 57% buy with no sell ratings, but profitability remains a challenge amid promotional headwinds. Risks include ongoing losses, competitive pressures, and a recent stock decline following guidance cuts. Investment opportunity hinges on execution toward profitability despite current bearish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
